140 related articles for article (PubMed ID: 38551114)
21. Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review.
Bradfield Strydom M; Khan S; Walpola RL; Ware RS; Tiralongo E
J Med Microbiol; 2023 May; 72(5):. PubMed ID: 37171871
[TBL] [Abstract][Full Text] [Related]
22. Biased Genotype Distributions of Candida albicans Strains Associated with 649 Clinical Vulvovaginal Candidiasis in China.
Pang Q; Liu W; Cui F; Kan S; Li X
Mycopathologia; 2022 Dec; 187(5-6):427-437. PubMed ID: 36209322
[TBL] [Abstract][Full Text] [Related]
23. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
Lynch ME; Sobel JD; Fidel PL
J Med Vet Mycol; 1996; 34(5):337-9. PubMed ID: 8912167
[TBL] [Abstract][Full Text] [Related]
24. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance.
Li X; Chen S; Lyu X; Tian J
Med Mycol; 2022 Nov; 60(11):. PubMed ID: 36328948
[TBL] [Abstract][Full Text] [Related]
25. Bioactive compounds with antifungal activity against pathogens isolated from pregnant woman: Gallesia integrifolia (garlic wood) is a promising treatment for vulvovaginal candidiasis.
de Souza ANV; Faria MGI; da Rocha CE; Philippsen GS; Silva GCC; da Silva GR; Inumaro RS; Gonçalves JE; Gazim ZC; Wietzikoski S; Lívero FADR; Seixas FAV; Wietzikoski Lovato EC
J Ethnopharmacol; 2022 Sep; 295():115403. PubMed ID: 35643209
[TBL] [Abstract][Full Text] [Related]
26. Species Distribution and Antifungal Susceptibility Profiles of Isolates from Women with Nonrecurrent and Recurrent Vulvovaginal Candidiasis.
Rolo J; Faria-Gonçalves P; Barata T; Oliveira AS; Gaspar C; Ferreira SS; Palmeira-de-Oliveira R; Martinez-de-Oliveira J; Costa-de-Oliveira S; Palmeira-de-Oliveira A
Microb Drug Resist; 2021 Aug; 27(8):1087-1095. PubMed ID: 33646045
[TBL] [Abstract][Full Text] [Related]
27. Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis.
Moreira D; Ruiz LS; Leite-Jr DP; Auler ME; Ramos RTB; Costa VT; Lara BR; Gasparetto A; Gandra RF; Melhem MSC; Paula CR
Mycopathologia; 2021 Jun; 186(3):411-421. PubMed ID: 34120275
[TBL] [Abstract][Full Text] [Related]
28. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam.
Anh DN; Hung DN; Tien TV; Dinh VN; Son VT; Luong NV; Van NT; Quynh NTN; Van Tuan N; Tuan LQ; Bac ND; Luc NK; Anh LT; Trung DM
BMC Infect Dis; 2021 Jun; 21(1):523. PubMed ID: 34082699
[TBL] [Abstract][Full Text] [Related]
29. Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates.
Alvendal C; Mohanty S; Bohm-Starke N; Brauner A
PLoS One; 2020; 15(9):e0238428. PubMed ID: 32941438
[TBL] [Abstract][Full Text] [Related]
30. Differential Response of
Salama OE; Gerstein AC
Antimicrob Agents Chemother; 2022 May; 66(5):e0240621. PubMed ID: 35446135
[TBL] [Abstract][Full Text] [Related]
31. An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis.
Rosati D; Bruno M; Jaeger M; Kullberg BJ; van de Veerdonk F; Netea MG; Ten Oever J
J Infect Dis; 2022 May; 225(10):1796-1806. PubMed ID: 32702099
[TBL] [Abstract][Full Text] [Related]
32. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
Fan S; Liu X; Wu C; Xu L; Li J
Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of homology and drug sensitivity of vaginal isolates of 10 patients with recurrent vulvovaginal candidiasis in recurrent episodes].
Zhang Z; Bai HH; Wang FJ; Li T; Zong XN; Shang CG; Liu ZH
Zhonghua Fu Chan Ke Za Zhi; 2020 Mar; 55(3):177-182. PubMed ID: 32268715
[No Abstract] [Full Text] [Related]
34. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Collins LM; Moore R; Sobel JD
J Low Genit Tract Dis; 2020 Jan; 24(1):48-52. PubMed ID: 31860575
[TBL] [Abstract][Full Text] [Related]
35. Antifungal effects of Lavandula binaludensis and Cuminum cyminum essential oils against Candida albicans strains isolated from patients with recurrent vulvovaginal candidiasis.
Minooeianhaghighi MH; Sepehrian L; Shokri H
J Mycol Med; 2017 Mar; 27(1):65-71. PubMed ID: 27751723
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Infectious Characteristics of Recurrent Vulvovaginal Candidiasis in Chengdu from 2018 to 2022.
Xu L; Jiang Y; Hu Z; Tang Y
Clin Lab; 2023 Aug; 69(8):. PubMed ID: 37560852
[TBL] [Abstract][Full Text] [Related]
37. [Microbiological findings in patients with recurrent vulvovaginal candidiasis in the Hradec Králové Faculty Hospital 1995-2002].
Buchta V; Spacek J
Ceska Gynekol; 2004 Jan; 69(1):7-14. PubMed ID: 15112380
[TBL] [Abstract][Full Text] [Related]
38. Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect against
Nikoomanesh F; Falahatinejad M; Černáková L; Dos Santos ALS; Mohammadi SR; Rafiee M; Rodrigues CF; Roudbary M
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109701
[No Abstract] [Full Text] [Related]
39. Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics.
Naeimi B; Mirhendi H; Khamisipour G; Sadeghzadeh F; Ahmadi B
J Med Microbiol; 2018 Nov; 67(11):1601-1607. PubMed ID: 30248002
[TBL] [Abstract][Full Text] [Related]
40. A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women.
Arastehfar A; Kargar ML; Mohammadi SR; Roudbary M; Ghods N; Haghighi L; Daneshnia F; Tavakoli M; Jafarzadeh J; Hedayati MT; Wang H; Fang W; Carvalho A; Ilkit M; Perlin DS; Lass-Flörl C
Front Microbiol; 2021; 12():655069. PubMed ID: 33995315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
